Petros Pharmaceuticals, Inc. (PTPI)

USD 0.35

(-29.78%)

Market Cap (In USD)

3.51 Million

Revenue (In USD)

5.82 Million

Net Income (In USD)

-8.16 Million

Avg. Volume

253.24 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.221-2.27
PE
-
EPS
-
Beta Value
2.283
ISIN
US71678J2096
CUSIP
71678J100
CIK
1815903
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. John David Shulman
Employee Count
-
Website
https://www.petrospharma.com
Ipo Date
2020-12-02
Details
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.